Baidu
map

心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2016 ESC专家共识：冠状动脉疾病和/或房颤患者出血后抗栓治疗管理

2016-10-27 欧洲心脏病学会 Eur Heart J. 2016 Oct 27.

冠状动脉疾病房颤出血抗栓

出血是冠状动脉疾病患者管理过程中常见的并发症，尤其是在急性冠脉综合征或接受PCI治疗和房颤患者中。本文主要针对冠状动脉疾病和/或房颤患者出血后抗栓治疗的管理提供了一个欧洲专家共识，包括停用哪些药物，开始应用哪些药物以及应用的时机。

中文标题：

2016 ESC专家共识：冠状动脉疾病和/或房颤患者出血后抗栓治疗管理

英文标题：

Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.

发布机构：

欧洲心脏病学会

发布日期：

2016-10-27

简要介绍：

出血是冠状动脉疾病患者管理过程中常见的并发症，尤其是在急性冠脉综合征或接受PCI治疗和房颤患者中。本文主要针对冠状动脉疾病和/或房颤患者出血后抗栓治疗的管理提供了一个欧洲专家共识，包括停用哪些药物，开始应用哪些药物以及应用的时机。

相关资料下载：
[AttachmentFileName(sort=100, fileName=2016 ESC专家共识：冠状动脉疾病和/或房颤患者出血后抗栓治疗管理)] GetToolGuiderByIdResponse(projectId=1, id=d36f81c0013223da, title=2016 ESC专家共识：冠状动脉疾病和/或房颤患者出血后抗栓治疗管理, enTitle=Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis., guiderFrom=Eur Heart J. 2016 Oct 27., authorId=null, author=, summary=出血是冠状动脉疾病患者管理过程中常见的并发症，尤其是在急性冠脉综合征或接受PCI治疗和房颤患者中。本文主要针对冠状动脉疾病和/或房颤患者出血后抗栓治疗的管理提供了一个欧洲专家共识，包括停用哪些药物，开始应用哪些药物以及应用的时机。, cover=, journalId=null, articlesId=null, associationId=62, associationName=欧洲心脏病学会, associationIntro=是目前在欧洲居于首要地位的心脏病学会，会员超过70000人、提供更新指南、调查数据、组织学术会议，ESC年会是心血管领域最大的会议。下设5个分会（超声心动图学会、心律学会、心衰学会、预防与康复学会及介入学会）。提供指南较全面，按年份排列。现提供有手机板本。, copyright=0, guiderPublishedTime=Thu Oct 27 00:00:00 CST 2016, originalUrl=, linkOutUrl=, content=出血是冠状动脉疾病患者管理过程中常见的并发症，尤其是在急性冠脉综合征或接受PCI治疗和房颤患者中。本文主要针对冠状动脉疾病和/或房颤患者出血后抗栓治疗的管理提供了一个欧洲专家共识，包括停用哪些药物，开始应用哪些药物以及应用的时机。<div><br> 拓展指南：<strong>与<font color="red">抗栓治疗</font>相关指南：</strong><br><ul><li><a href="//www.sandwebs.com/guideline/show_article.do?id=f54b51c001321af7" title="2016 急性冠状动脉综合征抗栓治疗合并出血防治多学科专家共识" target="_blank">2016 急性冠状动脉综合征抗栓治疗合并出血防治多学科专家共识</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=d9ff71c0012a635e" title="2016 抗栓治疗消化道损伤防治中国专家建议（2016·北京）" target="_blank">2016 抗栓治疗消化道损伤防治中国专家建议（2016·北京）</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=dbffb1c0012a08d7" title="2012 ACCP抗栓治疗和血栓形成预防临床实践指南（第9版）" target="_blank">2012 ACCP抗栓治疗和血栓形成预防临床实践指南（第9版）</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=66bd61c0010952e7" title="2014 缺血性卒中/短暂性脑缺血发作患者合并心房颤动的筛查及抗栓治疗中国专家共识" target="_blank">2014 缺血性卒中/短暂性脑缺血发作患者合并心房颤动的筛查及抗栓治疗中国专家共识</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=4d8cc1c0010e90b9" title="2014 SOGC 妊娠期静脉血栓的抗栓治疗指南（NO. 308）" target="_blank">2014 SOGC 妊娠期静脉血栓的抗栓治疗指南（NO. 308）</a></li> 更多信息请点击：<a href="//www.sandwebs.com/guideline/list.do?q=%E6%8A%97%E6%A0%93%E6%B2%BB%E7%96%97" target="_blank">有关抗栓治疗更多指南</a></ul></div>, tagList=[TagDto(tagId=1993, tagName=冠状动脉疾病), TagDto(tagId=364, tagName=房颤), TagDto(tagId=2131, tagName=出血), TagDto(tagId=11505, tagName=抗栓)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6509, appHits=308, showAppHits=0, pcHits=4172, showPcHits=2542, likes=157, shares=7, comments=10, approvalStatus=1, publishedTime=Tue Nov 01 15:33:49 CST 2016, publishedTimeString=2016-10-27, pcVisible=1, appVisible=1, editorId=5295957, editor=lili, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=lili, createdTime=Tue Nov 01 15:33:49 CST 2016, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 05:27:41 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2016 ESC专家共识：冠状动脉疾病和/或房颤患者出血后抗栓治疗管理)])
2016 ESC专家共识：冠状动脉疾病和/或房颤患者出血后抗栓治疗管理
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1057183, encodeId=17c5105e1836a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:10:21 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057182, encodeId=3f22105e182eb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:10:15 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883972, encodeId=f7d48839e208, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200909/9a3761a976f143de854e9450112be536/a11c94d7fc4a4712869765312d957a25.jpg, createdBy=8db52453263, createdName=123fc608m32暂无昵称, createdTime=Wed Sep 09 21:25:24 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160872, encodeId=169c1608e2f1, content=正在学习，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/500fb0522c49411a993af4fd64f0b4a1/33d6c69db19f47138b3abca21d043b69.jpg, createdBy=a0501991324, createdName=fay370, createdTime=Wed Dec 07 09:40:54 CST 2016, time=2016-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154690, encodeId=dab4154690f2, content=抗栓治疗管理。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Nov 10 06:44:33 CST 2016, time=2016-11-10, status=1, ipAttribution=)]
    2021-10-03 H8888888

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1057183, encodeId=17c5105e1836a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:10:21 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057182, encodeId=3f22105e182eb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:10:15 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883972, encodeId=f7d48839e208, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200909/9a3761a976f143de854e9450112be536/a11c94d7fc4a4712869765312d957a25.jpg, createdBy=8db52453263, createdName=123fc608m32暂无昵称, createdTime=Wed Sep 09 21:25:24 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160872, encodeId=169c1608e2f1, content=正在学习，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/500fb0522c49411a993af4fd64f0b4a1/33d6c69db19f47138b3abca21d043b69.jpg, createdBy=a0501991324, createdName=fay370, createdTime=Wed Dec 07 09:40:54 CST 2016, time=2016-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154690, encodeId=dab4154690f2, content=抗栓治疗管理。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Nov 10 06:44:33 CST 2016, time=2016-11-10, status=1, ipAttribution=)]
    2021-10-03 H8888888

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1057183, encodeId=17c5105e1836a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:10:21 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057182, encodeId=3f22105e182eb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:10:15 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883972, encodeId=f7d48839e208, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200909/9a3761a976f143de854e9450112be536/a11c94d7fc4a4712869765312d957a25.jpg, createdBy=8db52453263, createdName=123fc608m32暂无昵称, createdTime=Wed Sep 09 21:25:24 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160872, encodeId=169c1608e2f1, content=正在学习，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/500fb0522c49411a993af4fd64f0b4a1/33d6c69db19f47138b3abca21d043b69.jpg, createdBy=a0501991324, createdName=fay370, createdTime=Wed Dec 07 09:40:54 CST 2016, time=2016-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154690, encodeId=dab4154690f2, content=抗栓治疗管理。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Nov 10 06:44:33 CST 2016, time=2016-11-10, status=1, ipAttribution=)]
    2020-09-09 123fc608m32暂无昵称

    学习！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1057183, encodeId=17c5105e1836a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:10:21 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057182, encodeId=3f22105e182eb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:10:15 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883972, encodeId=f7d48839e208, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200909/9a3761a976f143de854e9450112be536/a11c94d7fc4a4712869765312d957a25.jpg, createdBy=8db52453263, createdName=123fc608m32暂无昵称, createdTime=Wed Sep 09 21:25:24 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160872, encodeId=169c1608e2f1, content=正在学习，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/500fb0522c49411a993af4fd64f0b4a1/33d6c69db19f47138b3abca21d043b69.jpg, createdBy=a0501991324, createdName=fay370, createdTime=Wed Dec 07 09:40:54 CST 2016, time=2016-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154690, encodeId=dab4154690f2, content=抗栓治疗管理。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Nov 10 06:44:33 CST 2016, time=2016-11-10, status=1, ipAttribution=)]
    2016-12-07 fay370

    正在学习，感谢！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1057183, encodeId=17c5105e1836a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:10:21 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057182, encodeId=3f22105e182eb, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:10:15 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883972, encodeId=f7d48839e208, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200909/9a3761a976f143de854e9450112be536/a11c94d7fc4a4712869765312d957a25.jpg, createdBy=8db52453263, createdName=123fc608m32暂无昵称, createdTime=Wed Sep 09 21:25:24 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160872, encodeId=169c1608e2f1, content=正在学习，感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/500fb0522c49411a993af4fd64f0b4a1/33d6c69db19f47138b3abca21d043b69.jpg, createdBy=a0501991324, createdName=fay370, createdTime=Wed Dec 07 09:40:54 CST 2016, time=2016-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154690, encodeId=dab4154690f2, content=抗栓治疗管理。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Nov 10 06:44:33 CST 2016, time=2016-11-10, status=1, ipAttribution=)]
    2016-11-10 jyzxjiangqin

    抗栓治疗管理。

    0

以上为热门评论，梅斯医学App还有更多内容
Baidu
map
Baidu
map
Baidu
map